Can hysterosalpingo-foam sonography replace hysterosalpingography as first-choice tubal patency test? A randomized non-inferiority trial


1Department of Reproductive Medicine, Amsterdam Reproduction and Development Research Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
2Department of Obstetrics and Gynaecology, Franciscus Hospital, Rotterdam, The Netherlands
3Department of Obstetrics and Gynaecology, Jeroen Bosch Hospital, Den Bosch, The Netherlands
4Department of Obstetrics and Gynaecology, OLVG Oost, Amsterdam, The Netherlands
5Centre for Reproductive Medicine, Amsterdam Reproduction and Development Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
6Department of Obstetrics and Gynaecology, Fluo Hospital, Almere, The Netherlands
7Department of Obstetrics and Gynaecology, Gelre Hospitals, Location Apeldoorn, Apeldoorn, The Netherlands
8Department of Obstetrics and Gynaecology, Rivierland Hospital, Tiel, The Netherlands
9Department of Reproductive Medicine and Gynaecology, University Medical Centre Utrecht, Utrecht, The Netherlands
10Department of Obstetrics and Gynaecology, Diakonessenhuis, Utrecht, The Netherlands
11Department of Obstetrics and Gynaecology, Spaarne Gasthuis, Haarlem, The Netherlands
12Department of Obstetrics and Gynaecology, Tergooi Hospital, Blaricum, The Netherlands
13Department of Obstetrics and Gynaecology, Amstelland Hospital, Amstelveen, The Netherlands
14Department of Obstetrics and Gynaecology, Lumen Hospital Groningen, Groningen, The Netherlands
15Department of Obstetrics and Gynaecology, Zuyderland Medical Center, Heerlen, The Netherlands
16Department of Obstetrics and Gynaecology, Deventer Hospital, Deventer, The Netherlands
17Department of Obstetrics and Gynaecology, Sint Antonius Hospital, Nieuwegein, The Netherlands
18Department of Obstetrics and Gynaecology, Stichting Nederlandse Diakonissen, Amsterdam, The Netherlands
19Department of Obstetrics and Gynaecology, Martini Hospital Groningen, Groningen, The Netherlands
20Department of Obstetrics and Gynaecology, Kliniek Zutphen, Zutphen, The Netherlands
21Department of Obstetrics and Gynaecology, Gelse Hospitals, Location Zutphen, Zutphen, The Netherlands
22Department of Obstetrics and Gynaecology, MCZ, Schijndel, The Netherlands
23Department of Obstetrics and Gynaecology, Medical Centre Leeuwarden, Leeuwarden, The Netherlands
24Department of Obstetrics and Gynaecology, Martini Hospital, Groningen, Groningen, The Netherlands
25Department of Obstetrics and Gynaecology, Maastricht University Medical Centre, Maastricht, The Netherlands
26Department of Obstetrics and Gynaecology, Deventer Hospital, Deventer, The Netherlands
27Department of Obstetrics and Gynaecology, Sint Antonius Hospital, Nieuwegein, The Netherlands
28Department of Obstetrics and Gynaecology, UMC Utrecht, Utrecht, The Netherlands
29Department of Obstetrics and Gynaecology, University Medical Centre Utrecht, Utrecht, The Netherlands
30Department of Obstetrics and Gynaecology, University Medical Centre, Groningen, Groningen, The Netherlands
31Department of Obstetrics and Gynaecology, Amsterdam Reproduction and Development Research Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
32Department of Obstetrics and Gynaecology, Amsterdam University Medical Center, Amsterdam, The Netherlands
33Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
34Department of Epidemiology & Data Science, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
35Department of Obstetrics and Gynaecology, Monash University, Clayton, VIC, Australia
36Aberdeen Centre for Women’s Health Research, King’s College, University of Aberdeen, Aberdeen, UK

*Correspondence address. Department of Reproductive Medicine, Amsterdam Reproduction & Development Research Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1118, 1081 HV Amsterdam, The Netherlands.

Submitted on April 12, 2021; resubmitted on January 27, 2022; editorial decision on February 8, 2022
Introduction

Tubal pathology is one of the main causes of female infertility with a prevalence between 11% and 30%, resulting from infections (often transmitted sexually, such as chlamydia and gonorrhoea), previous surgery or endometriosis (Hull et al., 1985; Collins et al., 1995; Snick et al., 1997; Farquhar et al., 2019). Considering that unilateral tubal pathology does not necessarily reduce pregnancy chances in comparison to no tubal pathology, the aim is to detect bilateral tubal pathology...
Effectiveness of hysterosalpingo-foam sonography

(Verhoeve et al., 2011; Tan et al., 2019). Therefore, evaluation of the fallopian tubes is a standard part of the fertility work-up.

Diagnostic laparoscopy with chromopertubation is considered the reference standard to assess tubal patency with direct visualization of the fallopian tubes and their surrounding pelvic structures (Mol et al., 1999; Saunders et al., 2011; NICE, 2013). As laparoscopy is invasive and expensive, it is deemed inappropriate for screening purposes in unselected infertile women (Jansen et al., 1997; NICE, 2013; ACOG, 2019).

Hysterosalpingography (HSG) is currently still considered as the first-choice tubal patency test during fertility work-up (NICE, 2013; ACOG, 2019). During HSG an iodinated contrast medium is flushed through the uterus and fallopian tubes while radiographs are performed. Although HSG is less invasive than laparoscopy, it is often experienced as painful and it results in exposure to ionising radiation and iodinated contrast medium (Saunders et al., 2011; Chauhan et al., 2013).

Hysterosalpingo-contrast sonography (HyCoSy) has been introduced as a more patient-friendly alternative. It relies on transvaginal ultrasound while flushing the uterus and fallopian tubes with echogenic contrast medium, during which the ovaries can be visualized as well. Its accuracy was shown to be comparable to that of HSG in predicting tubal patency (Randolph et al., 1986; Reis et al., 1998; Dijkstra et al., 2000; Saunders et al., 2011; Lim et al., 2015). However, the commonly used echogenic contrast medium for HyCoSy, Echovist® (Bayer Schering Pharma AG, Berlin, Germany), was found to potentially cause allergic reactions and is no longer licensed for gynaecological use (Luciano et al., 2014). An alternative medium is a combination of air and saline, which requires a very quick evaluation of the fallopian tubes, as the air bubbles rapidly disappear from the saline (Heikkinen et al., 1995). SonoVue® (sulphur hexafluoride; Bracco International BV, Amsterdam, The Netherlands) is another contrast medium for sonographic tubal patency testing. This second-generation microbubble contrast agent with a gas core generates useful patterns in 2- and 3-dimensional ultrasound, and it is a safe agent regarding consequences of intravasation (Lanzani et al., 2009; Zhou et al., 2012; Exacoustos et al., 2013; He et al., 2013). Although SonoVue® is not registered for tubal patency testing, it is still used in studies and clinical practice (Wang & Qian, 2016).

Given the unstable patterns of air and saline, a more stable echogenic medium was introduced in 2011: ExEm-foam® (IQ Medical Ventures BV, Rotterdam, The Netherlands) which is currently the only registered commercial contrast for tubal patency testing in ultrasound. Like HyCoSy, hysterosalpingo-foam sonography (HyFoSy) appears to be as accurate in diagnosing tubal patency as HSG (Maheux-Lacroix et al., 2014), although recent studies found HyFoSy to have a higher diagnostic accuracy than HyCoSy (Lim et al., 2015; Ludwin et al., 2017; Piccioni et al., 2017). HyFoSy is also considered to be less painful and less time-consuming than HSG (Dreyer et al., 2014; Van Schoubroeck et al., 2015a; Tanaka et al., 2018).

The effectiveness of any medical test should ultimately be judged by its ability to affect patient-important outcomes (AHRQ, 2008; Guyatt et al., 2008; Schünemann et al., 2016). In couples suffering from infertility, pregnancy outcomes are the most important goal and should guide the choice of tests, while treatment burden and inconvenience can be a second criterion.

So far, the effects of HyFoSy on pregnancy outcomes have only been studied in relatively small or observational studies (Emanuel et al., 2012; Exacoustos et al., 2015; Van Schoubroeck et al., 2015b; Tanaka et al., 2018). We hypothesized that HyFoSy and HSG have similar effectiveness in terms of pregnancy outcomes. Randomized trials are well-suited to evaluate the comparative effectiveness of medical tests and testing strategies, even though straightforward allocation to two testing strategies is not always the most efficient design (Bossuyt et al., 2000; Gazelle et al., 2011). We conducted a multicentre randomized trial with a discordancy design to compare HyFoSy to HSG in guiding clinical management in infertile couples, with ongoing pregnancy leading to live birth as the primary outcome.

Materials and methods

Study design and participants

The FOAM study was a multicentre prospective comparative non-inferiority trial of HyFoSy versus HSG, with randomization of couples with discordant test results. The study was performed in 26 hospitals in The Netherlands (4 academic hospitals, 15 teaching and 7 non-teaching hospitals) within the infrastructure of the Dutch Consortium for Healthcare Evaluation and Research in Obstetrics and Gynaecology (NVOG Consortium; https://www.zorgevaluatienederland.nl).

Infertile women between 18 and 41 years of age who were scheduled for tubal patency testing as part of the fertility work-up were eligible to participate. Women with anovulatory cycles not responding to ovulation induction, endometriosis, severe male factor (total motile sperm count < 1 × 10⁹/ml) or a known iodine contrast allergy could not participate.

The study was approved by the National Central Committee on Research involving Human Subjects (CCMO, The Netherlands; ref. no. NLS0484.029.14) and by the ethics committee and institutional review board of the Amsterdam UMC, location VU University Medical centre (ref. no. 2014.454). The board of directors of all participating hospitals approved local execution of the study. The study was registered prospectively (original no. NTR4746; new no. NL4587; https://www.trialregister.nl), and the study protocol has been published previously (van Rijswijk et al., 2018). Trial oversight was provided by the ethics committee of the Amsterdam UMC, location VU University Medical centre. All participants provided written informed consent. Data monitoring was performed in accordance with the Good Clinical Practice guidelines by dedicated research nurses of the Dutch consortium for Healthcare Evaluation and Research in Obstetrics and Gynaecology (NVOG Consortium; https://www.zorgevaluatienederland.nl) in each of the participating centres. All gynaecologists, fertility doctors or ultrasound technicians were trained in their centre in the performance of HyFoSy by V.M., K.D., J.R. or N.W. The first, second, third and last authors vouch for accuracy and completeness of the data and analyses and for the fidelity of the trial to the protocol.

Randomization and blinding

Eligible women were informed about the study during a regular outpatient visit by their gynaecologist or fertility doctor. After providing written informed consent, participating women underwent both HyFoSy...
and HSG, in a randomly assigned order. This randomization was performed using ALEA 2.2, a web-based interface displaying the allocated order from a computer-generated randomization sequence (FormsVision BV, Abcoude, The Netherlands), stratified for centre with randomly permuted blocks, with block size varying between two and four. The physician who performed the second assigned test was blinded from the results of the first performed test. Women in whom the results of HyFoSy and HSG were discordant were randomized in a 1:1 ratio to either a clinical management strategy guided by HyFoSy or one guided by HSG using ALEA 2.2, non-centre-stratified with randomly permuted blocks, with block size varying between two and four.

Procedures

Both HyFoSy and HSG were performed within the two weeks of the follicular phase of the cycle after complete cessation of menstrual bleeding. Women were allowed to take pain medication (e.g. paracetamol or naproxen) before both tubal patency tests.

During HyFoSy 5–10 cc of echogenic foam was infused in the uterine cavity through a small cervical balloon-less GIS® catheter (IQ Medical Ventures BV, Rotterdam, The Netherlands). The foam was created by rigorously mixing 5 cc ExEm-gel® (IQ Medical Ventures BV, Rotterdam, The Netherlands) with 5 cc sterile purified water (IQ Medical Ventures BV, Rotterdam, The Netherlands). This foam is stable to show echogenicity for at least 5 min (Emanuel et al., 2012). The created foam was slowly infused into the uterine cavity during 2-dimensional transvaginal sonography, and subsequent into the fallopian tubes to assess patency (Fig. 1). Type of ultrasound system and machine settings depended on the local situation. Training before performing HyFoSy was mandatory.

HSG was performed according to the local protocol. A vacuum cervical cup, metal cannula (hysterophore) or a balloon catheter was used to infuse 5–10 cc contrast medium into the uterine cavity and fallopian tubes. The type of contrast medium, oil- or water-based, depended on local protocols. During instillation of the contrast medium, six to eight radiographs were made to assess the uterine cavity and patency of the fallopian tubes.

Test results of HyFoSy and HSG were categorized as: normal, one- or double-sided tubal pathology. The results of the two tests were then compared with decide whether they were concordant or discordant. Concordant test results were those leading to the same classification: normal/normal, one-sided tubal pathology/one-sided tubal pathology or double-sided tubal pathology/double-sided tubal pathology. No distinction was made between the side of the one-sided tubal pathology, as this has no consequences for the subsequent fertility management. Discordant was defined as conflicting test results. Test results were defined as inconclusive test results when the procedure was not completed successfully or was interrupted by technical or medical complications.

Subsequent fertility management was either based on the results of both discordant tests or, in case of discordant results, based on the results of the randomly assigned test. In case of bilateral or unilateral tubal patency, planned fertility treatment was initiated according to the prognosis for natural conception (Hunault et al., 2005) and the Dutch guideline (NVOG, 2015). If the chances of natural conception within 12 months exceeded 30%, expectant management for at least 6 months was advised before starting intrauterine insemination (IUI). In case the chances of natural conception were < 30%, women were advised to start IUII eventually followed by IVF. In case of bilateral occlusion, diagnostic laparoscopy with chromopertubation was performed to evaluate tubal pathology. If bilateral occlusion was confirmed, IVF was initiated. When at least one tube was patent during laparoscopy fertility treatment was based on the Hunault prognosis for natural conception (Hunault et al., 2005). Women with polycystic ovary syndrome continued with ovulation induction, once bilateral or unilateral tubal patency was confirmed.

Data were collected until 12 months after randomization in the study in a structured electronic case report form. If a pregnancy had occurred within 12 months, the outcome of that pregnancy was followed even if it exceeded 12 months. If the necessary information could not be extracted from the medical record, women received a questionnaire about pregnancy outcomes.

Outcomes

The primary outcome for the comparison of the two strategies was ongoing pregnancy leading to live birth within 12 months after inclusion. Ongoing pregnancy was defined as an intrauterine pregnancy with a heartbeat during ultrasound examination between 10 and 12 weeks of pregnancy. Live birth was defined as a live birth after 24 weeks of gestation.

Secondary outcomes reported here were: concordance between HyFoSy and HSG, pain score (measured by Visual Analogue Scale (VAS); ranging from 0.0 to 10.0 cm), time to ongoing pregnancy leading to live birth, biochemical pregnancy (defined as a positive pregnancy test or an increase in human chorionic gonadotropin combined with menstrual bleeding and absence of ultrasound visible pregnancy), miscarriage (defined as the presence of non-viability on ultrasound or spontaneous loss of pregnancy), ectopic pregnancy (defined as an embryo implanted outside the uterine cavity), multiple pregnancy (defined as a pregnancy of two or more foetuses) and preterm birth rate (defined as a delivery before 37 weeks of pregnancy). Costs and
cost-effectiveness were a prespecified secondary outcome and will be reported elsewhere. CORE outcomes (Duffy et al., 2020) are presented in Supplementary Table S1.

Statistical analysis
The effect on pregnancy outcomes of clinical management based on HyFoSy versus clinical management based on HSG was expressed as a difference, with 95% confidence interval, in the proportion of live births within 12 months in an intention-to-treat analysis.

To evaluate the pregnancy outcomes in a strategy in which management would be guided by HyFoSy, we studied the live birth rates in the subgroup with inconclusive results, in the subgroup with discordant results, and—for the subgroup with discordant test results—in the women randomly allocated to management guided by HyFoSy. To estimate the total number of live births, we added the results in each of the three subgroups, weighted by the corresponding fraction of the total study group.

We similarly estimated the pregnancy outcomes for a strategy in which management would be guided by HSG, by studying the live birth rates in the inconclusive group, the concordant group, and in the subgroup with discordant test results randomly allocated to management guided by HSG. Here also, we weighted each of these three subgroups by the corresponding fractions in the total study group. The subgroup with inconclusive results was included in both strategies, since we reasoned that the alternative procedure would be invoked in case one of the procedures was inconclusive, and, optionally, a diagnostic laparoscopy to guide clinical management. In these cases, a choice for the initial test, HSG or HyFoSy, would not lead to a difference in clinical management and, hence, not in outcomes either.

Since the difference in live births between the two strategies is driven by the difference in live birth rates in the discordant subgroup, randomly allocated to either HyFoSy or HSG, we could estimate this difference as the difference between the randomized groups, multiplied by the fraction of discordant test results in the total study group. Similarly, the 95% CI in the randomized subgroup was multiplied by the same fraction of women with discordant test results (Lu and Gatsonis, 2013).

The sample size calculation was guided by a non-inferiority hypothesis, in which we wanted to exclude a decrease of 2% in ongoing pregnancy leading to live birth among women with discordant results with clinical management relying on the HyFoSy results instead of on the HSG results. A narrow non-inferiority margin was chosen, as we anticipated that a difference of more than 2% would be clinically relevant to infertile couples. We assumed a 50% ongoing pregnancy rate within 12 months after tubal testing, with no difference between management guided by either HyFoSy or HSG. The total sample size was guided by the anticipated fraction of women with discordant results (Lu and Gatsonis, 2013). Assuming that this fraction with discordant results was 7% (Emanuel et al., 2012), the non-inferiority margin in the discordant results would be 29% (2% divided by 7%). To achieve at least 80% power to reject inferiority at a 5% significance level, we needed to randomize 74 women with discordant results; the total number of included women would then have to be 1057 (74 divided by 7%). To account for 10% lost to follow-up, our goal was to include 1163 women, resulting in 82 women with discordant results.

Additional sensitivity analyses were performed excluding women who were not eligible after reassessment, who did not receive assigned tests, or had a different order of tests than allocated. No interim analyses were performed. Missing data were assumed to be missing at random.

Mean pain scores for HyFoSy and HSG were compared using a paired samples t-test. To assess whether the mean pain scores were affected by the order (HyFoSy first or HSG first), an independent samples t-test of the difference in scores was performed. Time to pregnancy was compared between the two groups of women with discordant results using the log-rank test. The cumulative ongoing pregnancy leading to live birth rates over time is visualized as Kaplan-Meier curves. Statistical analysis was performed using IBM SPSS Statistics for Windows, version 26.0 (IBM Corp., Armonk, NY, USA).

Results
Between 7 May 2015 and 25 January 2019, 1862 women were registered as eligible (Fig. 2). A total of 1160 consenting women were assigned to undergo the two tubal patency tests, in random order (HyFoSy–HSG, n = 576, and HSG–HyFoSy, n = 584), of which 1026 received both tests and were included in the analysis (36 lost to follow-up, 24 no tests performed and 74 only one test performed). Table I presents the baseline characteristics of the study group.

Table II shows the results of HyFoSy versus HSG. In 97 (9.5%) of the 1026 women, HyFoSy was inconclusive, 30 (2.9%) had an inconclusive HSG, and in 9 (0.9%), both tests were inconclusive. In 747 women (73%) conclusive tests results were concordant. HyFoSy was more often inconclusive (10% vs. 4%) and less often normal (77% vs. 83%), whereas the proportion of women with one- or dual-sided pathology was comparable (13% vs. 13%).

In 38 of the 143 women with discordant test results, randomization was either declined by the participating woman or the study protocol was not fully adhered by the local investigator. The 105 other participants were randomly assigned to clinical management guided by either the results of HyFoSy (n = 54) or HSG (n = 51; Fig. 2). Table I also presents the baseline characteristics of the women with discordant test results randomly allocated to management based on HyFoSy or HSG. The baseline characteristics were similar in the two groups.

Supplementary Tables SII and SIII show the results of HyFoSy versus HSG allocated by the order of the tests (HyFoSy–HSG and HSG–HyFoSy). Supplementary Table SIV shows the management decisions taken in the subgroup with discordant results who agreed to be randomized. The prognosis for natural conception was comparable between the HyFoSy group and the HSG group. In addition, a comparable percentage underwent ovulation induction, ovulation induction followed by IUI or IVF, IUI (with or without mild ovarian hyper stimulation) alone, IUI followed by IVF/ICSI or IVF/ISCI alone.

Outcomes
Of the 136 women with an inconclusive test result on one or both tests, 55 (40%) experienced an ongoing pregnancy leading to live birth
within 12 months (Fig. 2). In the group of 747 with concordant test results, 361 (48%) experienced a live birth (Fig. 2).

Table III shows the ongoing pregnancy leading to live birth rates with clinical management based on the results of HyFoSy versus HSG. An ongoing pregnancy leading to live birth was observed in 22 of the 54 women (41%) randomly assigned to HyFoSy and in 25 of the 51 women (49%) randomly assigned to HSG (Difference -8%; 95% CI: -27% to 10%). No ectopic pregnancies or stillbirths were reported among the women with discordant results.

In total, clinical management based on the results of HyFoSy was estimated to lead to a live birth in 474 of 1026 women (46%) versus 486 of 1026 (47%) for management based on HSG (Difference -1.2%; 95% CI: -3.4% to 1.5%) (Table III). Given the 2% pre-defined margin, statistically significant non-inferiority of HyFoSy relative to HSG in terms of the effect of live births could not be demonstrated ($P = 0.27$). Time to ongoing pregnancy leading to live birth for the women with discordant results randomized for either management based on HyFoSy or HSG was comparable (Fig. 3).

Sensitivity analyses revealed no substantial differences compared with the primary analysis (results not shown).

VAS pain scores for HyFoSy were reported by 1003 of the 1026 women (98%) and VAS scores for HSG were reported by 953 of the 1026 women (93%). HyFoSy was experienced as significantly less painful than HSG ($P < 0.001$). The mean VAS pain score for HyFoSy was 3.1 (SD 2.2) and the mean VAS pain score for HSG was 5.4 (SD 2.5). Although the mean VAS pain score of HyFoSy was not affected by the order of the tests ($P = 0.57$), the mean VAS pain score of HSG was higher when it was administered first, before HyFoSy ($P = 0.01$). There was no significant difference in the mean VAS pain scores for HSG when either oil-based contrast medium was used ($n = 697$; mean VAS pain score 5.5, SD 2.5) or water-based contrast medium ($n = 281$, mean VAS pain score 5.3, SD 2.7; $P = 0.23$).

**Discussion**

In infertile women scheduled for tubal patency testing during their fertility work-up, management based on the results of either HyFoSy or HSG leads to similar pregnancy outcomes, while HyFoSy is associated with significantly less pain. Though the estimated difference in
proportions of women with a live birth within 12 months was only 1.2%, we could not demonstrate statistically significant non-inferiority of HyFoSy relative to HSG; the pre-defined 2% margin is included in the 95% CI. The direct therapeutic effect of tubal flushing was not taken into account.

Our study has several strengths and limitations. Major strengths of our study are the large sample size and the efficient paired design with randomization of women with discordant results and subsequent fertility management. An advantage of our study design is the efficiency, as every woman acts as her own control in comparing test results, which reduced our sample size compared with a traditional randomized trial. Our sample size was guided by the expected fraction of discordant results based on available literature (Emanuel et al., 2012). Additionally, we precluded observer bias by blinding the physician that performed the second test from the results of the first test. Other strengths are the execution of our trial according to a

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>All women (N = 1026)</th>
<th>Discordant results management based on HyFoSy (n = 54)</th>
<th>Discordant results management based on HSG (n = 51)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>33.0 (30.0–36.0)</td>
<td>33.0 (29.0–36.3)</td>
<td>32.0 (29.0–36.0)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>23.4 (21.0–26.6)</td>
<td>24.2 (21.4–27.9)</td>
<td>24.3 (21.3–27.5)</td>
</tr>
<tr>
<td>Current smoker</td>
<td>128/1008 (13)</td>
<td>13 (24)</td>
<td>6 (12)</td>
</tr>
<tr>
<td>Ethnicityd</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>830 (81)</td>
<td>42 (78)</td>
<td>42 (82)</td>
</tr>
<tr>
<td>Other</td>
<td>139 (14)</td>
<td>12 (22)</td>
<td>8 (16)</td>
</tr>
<tr>
<td>Unknown</td>
<td>57 (5)</td>
<td>0 (0)</td>
<td>1 (2)</td>
</tr>
<tr>
<td>Duration infertility (months)</td>
<td>19.0 (15.0–26.2)</td>
<td>20.0 (14.8–24.0)</td>
<td>21.0 (16.7–36.3)</td>
</tr>
<tr>
<td>Primary infertility</td>
<td>683 (67)</td>
<td>34 (63)</td>
<td>30 (59)</td>
</tr>
<tr>
<td>Duration of menstrual cycle (days)</td>
<td>28.0 (28.0–30.0)</td>
<td>28.0 (28.0–30.0)</td>
<td>30.0 (28.0–31.0)</td>
</tr>
<tr>
<td>High risk of tubal pathologyf</td>
<td>135/888 (15)</td>
<td>11/50 (22)</td>
<td>10/47 (21)</td>
</tr>
<tr>
<td>Total motile sperm count in male partner</td>
<td>54.8 (22.0–122.0)</td>
<td>47.5 (12.0–89.8)</td>
<td>49.0 (13.3–112.3)</td>
</tr>
</tbody>
</table>

Data are medians (IQRs) or n (%), unless otherwise indicated; N is equal to the total number of women, unless otherwise indicated.

aData on BMI were available for 999 women.
bData on BMI were available for 53 versus 49 women.
cData on maternal smoking were available for 1008 women.
dReported by clinicians.
eData on duration of menstrual cycle were available for 1022 women.
fDefined as positive Chlamydia Antibody titre, symptomatic Chlamydia infection (pelvic inflammatory disease) in the past, ectopic pregnancy or unilateral tubectomy in the past, ruptured appendixis or peritonitis in the past, or pelvic surgery in the past.
gData on the risk of tubal pathology were available for 888 women.
hData on the risk of tubal pathology were available for 50 versus 47 women.
iData on total motile sperm count were available for 995 men.
jData on total motile sperm count were available for 54 versus 48 men.
HyFoSy, hysterosalpingo-foam sonography; HSG, hysterosalpingography.

<table>
<thead>
<tr>
<th></th>
<th>Normal</th>
<th>One-sided tubal pathology</th>
<th>Double-sided tubal pathology</th>
<th>Inconclusive</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>HyFoSy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td>702 (68%)</td>
<td>52 (5%)</td>
<td>10 (1%)</td>
<td>27 (3%)</td>
<td>791 (77%)</td>
</tr>
<tr>
<td>One-sided tubal pathology</td>
<td>46 (4%)</td>
<td>35 (3%)</td>
<td>7 (1%)</td>
<td>2 (0%)</td>
<td>90 (9%)</td>
</tr>
<tr>
<td>Double-sided tubal pathology</td>
<td>19 (2%)</td>
<td>9 (1%)</td>
<td>10 (1%)</td>
<td>1 (0%)</td>
<td>39 (4%)</td>
</tr>
<tr>
<td>Inconclusive</td>
<td>88 (9%)</td>
<td>8 (1%)</td>
<td>1 (0%)</td>
<td>9 (1%)</td>
<td>106 (10%)</td>
</tr>
<tr>
<td>Total</td>
<td>855 (83%)</td>
<td>104 (10%)</td>
<td>28 (3%)</td>
<td>39 (4%)</td>
<td>1,026 (100%)</td>
</tr>
</tbody>
</table>

The completed tests are indicated by the dashed line. Concordance between HyFoSy and HSG is shown in the diagonal blue boxes; discordance between HyFoSy and HSG is illustrated in red; inconclusive is illustrated in italic.
previously published protocol, the mandatory training before performing HyFoSy, and women with various causes of infertility included. Our study also has some limitations. A number of eligible women declined participation, most often because of the burden of an additional test. The number of inconclusive test results on one or both tests was higher than anticipated. This might be explained by the operator-dependency and learning-curve of performing HyFoSy, although training was mandatory. Another possible explanation is that most of the women underwent both tubal patency tests on the same day in a relatively small time window, which might have resulted in interference of contrasts for either test. Even though Supplementary Tables SII and SIII show no clear evidence for interference. Thirty-eight women with discordant results could not be included in the randomized comparison; they either declined to be randomized or the local investigator decided not to follow the study protocol. A hard copy informed consent form was missing in 32 women and could not be traced, and these women were excluded from analysis. Finally, current guidelines advise to perform a tubal patency test only in selected women with a high risk for tubal pathology (NVOG, 2015; ACOG, 2019). Before onset of our study, international guidelines advised to perform a tubal patency test in all women during fertility work-up. Therefore, in our study majority of the women (85%) had a low risk for tubal pathology. Whether or not to perform a diagnostic tubal patency test during fertility work-up is still subject of debate, but this does not take the direct therapeutic effect of tubal flushing into account.

Before the start of our study, there were no RCTs directly comparing HyFoSy with HSG in terms of management strategies and subsequent pregnancy outcomes. Only small observational studies reported on pregnancy rates after HyFoSy, which varied from 19% within 3 months till 43% within 6 months (Emanuel et al., 2012; Exacoustos et al., 2015; Tanaka et al., 2018). Another observational study reported 55% pregnancies after HyFoSy, although follow-up duration varied largely (3–42 months; Van Schoubroeck et al., 2015a,b). So far, no detrimental effect of HyFoSy on fecundity was found in previous studies. Our study found overall pregnancy rates of 46–47% within 12 months after HyFoSy and HSG. HyFoSy with the use of ExEm-foam seems safe, although the number of studies on possible complications is limited. Recently, one case of cutaneous small-vessel vasculitis developed after HyFoSy was reported (Ludwin et al., 2019).

### Table III  Ongoing pregnancy leading to live birth with clinical management based on the results of hysterosalpingo-foam sonography (HyFoSy) versus hysterosalpingography (HSG) based on intention-to-treat analysis.

<table>
<thead>
<tr>
<th>Findings</th>
<th>n</th>
<th>Management based on HyFoSy</th>
<th>Management based on HSG</th>
<th>Difference (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inconclusive</td>
<td>136 (13%)</td>
<td>55 (40%)</td>
<td>55 (40%)</td>
<td>0 (^a)</td>
</tr>
<tr>
<td>Concordant</td>
<td>747 (73%)</td>
<td>361 (48%)</td>
<td>361 (48%)</td>
<td>0 (^a)</td>
</tr>
<tr>
<td>Discordant</td>
<td>143 (14%)</td>
<td>22/54 (41%)</td>
<td>25/51 (49%) (^b)</td>
<td>–8% (–27% to 10%)</td>
</tr>
<tr>
<td>Total</td>
<td>1,026 (100%)</td>
<td>474 (46%)</td>
<td>486 (47%) (^b)</td>
<td>–1.2% (–3.4% to 1.5%)</td>
</tr>
</tbody>
</table>

\(^a\) In participants with inconclusive or concordant results, management would not differ depending on whether the strategy had been based on HyFoSy or on HSG, and the difference is 0 by definition.

\(^b\) As observed in the randomized trial.

\(^\text{Estimated, based on the number of live births observed in the group with concordant results, the group with inconclusive results, and the randomized subgroups, each weighted by their corresponding fraction of the total group. Intention-to-treat analysis.}\)

### Figure 3. Time to ongoing pregnancy leading to live birth for management based on hysterosalpingo-foam sonography (HyFoSy) compared to hysterosalpingography (HSG). (A) Among discordant women (n = 105). (B) Among all women (N = 1026).
More research is needed. In our trial, eight infants had congenital anomalies (Supplementary Table S5). Contrary to HyFoSy, the fertility-enhancing effect and potential complications of HSG have been evaluated to a greater extent (Fang et al., 2018; Wang et al., 2019, 2020; Roest et al., 2021). Especially the use of oil-based contrast during HSG compared with water-based contrast results in higher ongoing pregnancy and live birth rates in couples with unexplained infertility and a low risk of tubal pathology (Dreyer et al., 2017). Since all women underwent both tubal patency tests in our study, no conclusions about therapeutic effects of HyFoSy could be drawn from our results.

HyFoSy was performed with 2-dimensional-transvaginal sonography; however, the use of 3-dimensional or Doppler imaging might increase the accuracy of HyFoSy and may add information on the ovum pick-up mechanism of the tubes. Even though evidence is limited, one could argue that these adjuvant ultrasound techniques make HyFoSy less operator-dependent and possibly less time consuming (Exacoustos et al., 2009; Maheux-Lacroix et al., 2014; Ludwin et al., 2017). Furthermore, reassessment of the images would be possible if storage of HyFoSy images is standardized. The comparison of diagnostic accuracy of HyFoSy to HSG and laparoscopy with dye was not included in this article but needs to be studied further.

In summary, this study showed that relying on either HyFoSy or HSG in infertile women leads to similar pregnancy outcomes, while HyFoSy is associated with significantly less pain. Although we could not exclude a slight decrease in pregnancy outcomes with management based on HyFoSy instead of HSG, we propose a two-step policy. Given the similar outcomes and lower pain scores, on these arguments HyFoSy can be preferred as first-choice tubal patency test during fertility work-up. In case of suspected tubal pathology or inconclusive results, further testing can be done. Before final conclusions on clinical management can be drawn, a head-to-head comparison between HyFoSy and HSG with oil-based contrast may be needed.

Supplementary data

Supplementary data are available at Human Reproduction online.

Data availability

De-identified individual participant data collected during the FOAM trial will be shared 1 year after publication of the results on request (mijatovic@amsterdamumc.nl). Approval of a proposal will be necessary before data will be shared. To gain access, requesters will need to sign an agreement form and confirm that the data will be used for the purpose for which access was granted.

Acknowledgements

We thank the women who participated in the trial, the hospitals and their staff (particularly the research nurses and other recruiting staff) for their contributions to this trial. We thank Prof. Dr Fulco van der Veen for his contribution in designing this study. Furthermore, we thank the staff of the Dutch Consortium for Healthcare Evaluation and Research in Obstetrics and Gynaecology (NVOG Consortium; https://www.zorgevaluatiенederland.nl) for logistic support, and Marijke M.C. van Nispen (database development) and the staff of the Clinical Research Unit of the Amsterdam UMC, location Academic Medical Centre for their help with the randomization program and the online database during this trial.

Authors’ roles


Funding

The FOAM study was an investigator-initiated study funded by ZonMw, The Netherlands organization for Health Research and Development (project number 837001504). ZonMw funded the whole project. IQ Medical Ventures provided the ExEm-foam® kits free of charge. The funders had no role in study design, collection, analysis and interpretation of the data. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Conflict of interest

K.D. reports travel and speaker fees from Guerbet. F.J.M.B. reports personal fees as a member of the external advisory board for Merck Serono, The Netherlands, and a research support grant from Merck Serono, outside the submitted work. C.B.L. reports speakers’ fee from Ferring in the past, and his department receives research grants from Ferring, Merck and Guerbet. J.S. reports a research agreement with Takeda on MR of motility outside the submitted work. M.v.W. reports leading the Netherlands Satellite of the Cochrane Gynaecology and Fertility Group. B.W.J.M. is supported by an NHMRC Investigator grant (GNT1176437). B.W.J.M. reports consultancy for Guerbet and research funding from Merck and Guerbet. V.M. reports non-financial support from IQ medicals ventures, during the conduct of the study; grants and personal fees from Guerbet, outside the submitted work. The other authors do not report conflicts of interest.

References


